| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75235 [S. F. W., J. D. M., A. F. G., D. P. C.], and National Cancer Institute/Navy Medical Oncology Branch, NIH, Bethesda, Maryland 20889 [S. F. W., J. D. M., B. E. J., T. T., A. F. G., D. P. C.]
Using immunoblotting techniques we studied the sera from small cell lung cancer and non-small cell lung cancer patients for antibodies directed against p53. We have also characterized the majority of these patients' tumors for p53 mutations. In the sera of 13% of the patients (4 of 40 small cell lung cancer and 2 of 6 non-small cell lung cancer) we found antibodies specific for the p53 tumor suppressor gene product. All of the antibody-positive patients tested had p53 missense mutations and expressed detectable p53 antigen in their tumor cell lines. No anti-p53 antibodies were detected in sera from patients whose tumor had p53 stop, splice/stop, splice, or frameshift mutations (n = 10). Thus, while we find that the ability of lung cancer patients to develop anti-p53 antibodies is correlated with the type of p53 mutation, many patients have tumors with missense p53 mutations and did not develop anti-p53 antibodies. The presence of p53 antibodies was not correlated to stage, prior treatment, sex, or survival. None of these lung cancer patient sera had measurable amounts of p53 antigen. By immunoblotting all six anti-p53 antisera we were able to detect a variety of mutant p53 proteins (including those from antibody-negative patients) and detected wild-type p53 protein. The development of anti-p53 antibodies represents an interesting model system for studying immune responses in cancer patients against mutant oncogene products.
1 S. F. W. is supported by the Deutsche Forschungsgemeinschaft.
2 Present address: Aichi Cancer Center, Research Institute, Laboratory of Chemotherapy, Kanokoden, Chikusa-ku, Nagoya 464, Japan.
3 Present address: Abteilung fuer Haematologie und Onkologie, Universita-etsklinikum Marburg, Baldingerstrasse, 3550 Marburg/L., Germany. To whom requests for reprints should be addressed, at Simmons Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8593.
Received 10/31/91. Accepted 5/15/92.
This article has been cited by other articles:
|
|
 |
|
  M. E. Couch, R. L. Ferris, J. A. Brennan, W. M. Koch, E. M. Jaffee, M. S. Leibowitz, G. T. Nepom, H. A. Erlich, and D. Sidransky Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7199 - 7206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Casiano, M. Mediavilla-Varela, and E. M. Tan Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer Mol. Cell. Proteomics, October 1, 2006; 5(10): 1745 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Nesterova, N. Johnson, C. Cheadle, S. E. Bates, S. Mani, C. A. Stratakis, I. Kahn, R. K. Gupta, and Y. S. Cho-Chung Autoantibody cancer biomarker: extracellular protein kinase a. Cancer Res., September 15, 2006; 66(18): 8971 - 8974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Bachmann, H. Bartsch, J. K. Gross, S. M. Maier, T. F. Gross, J. L. Workman, J. A. James, A. D. Farris, B. Jung, C. Franke, et al. Autoimmunity as a Result of Escape from RNA Surveillance J. Immunol., August 1, 2006; 177(3): 1698 - 1707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Egloff, L. A. Vella, and O. J. Finn Cyclin B1 and Other Cyclins as Tumor Antigens in Immunosurveillance and Immunotherapy of Cancer Cancer Res., January 1, 2006; 66(1): 6 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR J. Immunol., November 1, 2005; 175(9): 5799 - 5808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Iwata, T. Fujita, N. Hirao, Y. Matsuzaki, T. Okada, H. Mochimaru, N. Susumu, E. Matsumoto, K. Sugano, N. Yamashita, et al. Frequent Immune Responses to a Cancer/Testis Antigen, CAGE, in Patients with Microsatellite instability-Positive Endometrial Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3949 - 3957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Zhang, C. A. Casiano, X.-X. Peng, J. A. Koziol, E. K. L. Chan, and E. M. Tan Enhancement of Antibody Detection in Cancer Using Panel of Recombinant Tumor-associated Antigens Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 136 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zwaveling, M. P. M. Vierboom, S. C. Ferreira Mota, J. A. Hendriks, M. E. Ooms, R. P. M. Sutmuller, K. L. M. C. Franken, H. W. Nijman, F. Ossendorp, S. H. van der Burg, et al. Antitumor Efficacy of Wild-Type p53-specific CD4+ T-Helper Cells Cancer Res., November 1, 2002; 62(21): 6187 - 6193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sugita, M. Geraci, B. Gao, R. L. Powell, F. R. Hirsch, G. Johnson, R. Lapadat, E. Gabrielson, R. Bremnes, P. A. Bunn, et al. Combined Use of Oligonucleotide and Tissue Microarrays Identifies Cancer/Testis Antigens as Biomarkers in Lung Carcinoma Cancer Res., July 15, 2002; 62(14): 3971 - 3979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yasuda, M. Takenoyama, Y. Obata, M. Sugaya, T. So, T. Hanagiri, K. Sugio, and K. Yasumoto Tumor-infiltrating B Lymphocytes as a Potential Source of Identifying Tumor Antigen in Human Lung Cancer Cancer Res., March 1, 2002; 62(6): 1751 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Tomkiel, H. Alansari, N. Tang, J. B. Virgin, X. Yang, P. VandeVord, R. L. Karvonen, J. L. Granda, M. J. Kraut, J. F. Ensley, et al. Autoimmunity to the Mr 32,000 Subunit of Replication Protein A in Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 752 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. J. Coomber and R. L. Ward Isolation of Human Antibodies against the Central DNA Binding Domain of p53 from an Individual with Colorectal Cancer Using Antibody Phage Display Clin. Cancer Res., September 1, 2001; 7(9): 2802 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V. Fedoseyeva, F. Boisgerault, N. G. Anosova, W. S. Wollish, P. Arlotta, P. E. Jensen, S. J. Ono, and G. Benichou CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice J. Immunol., June 1, 2000; 164(11): 5641 - 5651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Soussi p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review Cancer Res., April 1, 2000; 60(7): 1777 - 1788. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Rohayem, K. Conrad, T. Zimmermann, and K.-H. Frank Comparison of the Diagnostic Accuracy of Three Commercially Available Enzyme Immunoassays for Anti-p53 Antibodies Clin. Chem., November 1, 1999; 45(11): 2014 - 2016. [Full Text] [PDF]
|
|
|
|
|
|
D. W. J. Coomber, N. J. Hawkins, M. A. Clark, and R. L. Ward Generation of Anti-p53 Fab Fragments from Individuals with Colorectal Cancer Using Phage Display J. Immunol., August 15, 1999; 163(4): 2276 - 2283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Zhang, E. K.L. Chan, X.-X. Peng, and E. M. Tan A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma J. Exp. Med., April 5, 1999; 189(7): 1101 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Brass, A. Racz, C. Bauer, D. Heckel, G. Sybrecht, and E. Meese Role of Amplified Genes in the Production of Autoantibodies Blood, April 1, 1999; 93(7): 2158 - 2166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. E. Shields, C. Gercel-Taylor, C. M. Yashar, T. C. Wan, W. A. Katsanis, J. A. Spinnato, and D. D. Taylor Induction of Immune Responses to Ovarian Tumor Antigens by Multiparity Reproductive Sciences, November 1, 1997; 4(6): 298 - 304. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Robbins p53 and Breast Cancer International Journal of Surgical Pathology, October 1, 1996; 4(2): 93 - 110. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Tan Meaning of Autoantibodies in Lupus-Like Syndromes Lupus, December 1, 1994; 3(6): 483 - 485. [PDF]
|
|
|
|
 |
|
 C. C. Harris and M. Hollstein Clinical Implications of the p53 Tumor-Suppressor Gene N. Engl. J. Med., October 28, 1993; 329(18): 1318 - 1327. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
